These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

529 related articles for article (PubMed ID: 32503572)

  • 1. Evolving therapy of adult acute lymphoblastic leukemia: state-of-the-art treatment and future directions.
    Samra B; Jabbour E; Ravandi F; Kantarjian H; Short NJ
    J Hematol Oncol; 2020 Jun; 13(1):70. PubMed ID: 32503572
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical trial update on bispecific antibodies, antibody-drug conjugates, and antibody-containing regimens for acute lymphoblastic leukemia.
    Liu D; Zhao J; Song Y; Luo X; Yang T
    J Hematol Oncol; 2019 Feb; 12(1):15. PubMed ID: 30736842
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment with anti CD19 chimeric antigen receptor T cells after antibody-based immunotherapy in adults with acute lymphoblastic leukemia.
    Danylesko I; Chowers G; Shouval R; Besser MJ; Jacoby E; Shimoni A; Nagler A; Avigdor A
    Curr Res Transl Med; 2020 Jan; 68(1):17-22. PubMed ID: 31882377
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New monoclonal antibodies and tyrosine kinase inhibitors in B-cell acute lymphoblastic leukemia.
    Lanza F; Maffini E; Saraceni F; Massari E; Rondoni M; Daghia G; Olivieri A; Cerchione C; Martinelli G
    Minerva Med; 2020 Oct; 111(5):478-490. PubMed ID: 32955830
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Current and future management of Ph/BCR-ABL positive ALL.
    Maino E; Sancetta R; Viero P; Imbergamo S; Scattolin AM; Vespignani M; Bassan R
    Expert Rev Anticancer Ther; 2014 Jun; 14(6):723-40. PubMed ID: 24611626
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Progress and Innovations in the Management of Adult Acute Lymphoblastic Leukemia.
    Jabbour E; Pui CH; Kantarjian H
    JAMA Oncol; 2018 Oct; 4(10):1413-1420. PubMed ID: 29931220
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The evolution of acute lymphoblastic leukemia research and therapy at MD Anderson over four decades.
    Jabbour E; Short NJ; Jain N; Haddad FG; Welch MA; Ravandi F; Kantarjian H
    J Hematol Oncol; 2023 Mar; 16(1):22. PubMed ID: 36927623
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Management of Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).
    Ottmann OG; Pfeifer H
    Hematology Am Soc Hematol Educ Program; 2009; ():371-81. PubMed ID: 20008223
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chemoimmunotherapy with inotuzumab ozogamicin combined with mini-hyper-CVD, with or without blinatumomab, is highly effective in patients with Philadelphia chromosome-negative acute lymphoblastic leukemia in first salvage.
    Jabbour E; Sasaki K; Ravandi F; Huang X; Short NJ; Khouri M; Kebriaei P; Burger J; Khoury J; Jorgensen J; Jain N; Konopleva M; Garcia-Manero G; Kadia T; Cortes J; Jacob J; Montalbano K; Garris R; O'Brien S; Kantarjian HM
    Cancer; 2018 Oct; 124(20):4044-4055. PubMed ID: 30307611
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Optimizing the treatment of acute lymphoblastic leukemia in younger and older adults: new drugs and evolving paradigms.
    Short NJ; Kantarjian H; Jabbour E
    Leukemia; 2021 Nov; 35(11):3044-3058. PubMed ID: 34172894
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inotuzumab ozogamicin in combination with low-intensity chemotherapy (mini-HCVD) with or without blinatumomab versus standard intensive chemotherapy (HCVAD) as frontline therapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukemia: A propensity score analysis.
    Jabbour EJ; Sasaki K; Ravandi F; Short NJ; Garcia-Manero G; Daver N; Kadia T; Konopleva M; Jain N; Cortes J; Issa GC; Jacob J; Kwari M; Thompson P; Garris R; Pemmaraju N; Yilmaz M; O'Brien SM; Kantarjian HM
    Cancer; 2019 Aug; 125(15):2579-2586. PubMed ID: 30985931
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antibody based therapy in relapsed acute lymphoblastic leukemia.
    Jammal N; Chew S; Jabbour E; Kantarjian H
    Best Pract Res Clin Haematol; 2020 Dec; 33(4):101225. PubMed ID: 33279181
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recent advances in the treatment of acute lymphoblastic leukemia.
    Rafei H; Kantarjian HM; Jabbour EJ
    Leuk Lymphoma; 2019 Nov; 60(11):2606-2621. PubMed ID: 31092071
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Blinatumomab or Inotuzumab Ozogamicin as Bridge to Allogeneic Stem Cell Transplantation for Relapsed or Refractory B-lineage Acute Lymphoblastic Leukemia: A Retrospective Single-Center Analysis.
    Stelmach P; Wethmar K; Groth C; Wenge DV; Albring J; Mikesch JH; Schliemann C; Reicherts C; Berdel WE; Lenz G; Stelljes M
    Clin Lymphoma Myeloma Leuk; 2020 Oct; 20(10):e724-e733. PubMed ID: 32646833
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Philadelphia chromosome-positive acute lymphoblastic leukemia at first relapse in the era of tyrosine kinase inhibitors.
    Abou Dalle I; Kantarjian HM; Short NJ; Konopleva M; Jain N; Garcia-Manero G; Garris R; Qiao W; Cortes JE; O'Brien S; Kebriaei P; Kadia T; Jabbour E; Ravandi F
    Am J Hematol; 2019 Dec; 94(12):1388-1395. PubMed ID: 31595534
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Monoclonal antibodies in frontline acute lymphoblastic leukemia.
    Chew S; Jammal N; Kantarjian H; Jabbour E
    Best Pract Res Clin Haematol; 2020 Dec; 33(4):101226. PubMed ID: 33279178
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Switching from salvage chemotherapy to immunotherapy in adult B-cell acute lymphoblastic leukemia.
    Kegyes D; Jitaru C; Ghiaur G; Ciurea S; Hoelzer D; Tomuleasa C; Gale RP
    Blood Rev; 2023 May; 59():101042. PubMed ID: 36732205
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Advances in the treatment of adults with newly diagnosed B-cell acute lymphoblastic leukemia: the role of frontline immunotherapy-based regimens.
    Short NJ; Kantarjian H; Jabbour E
    Leuk Lymphoma; 2024 Oct; 65(10):1405-1417. PubMed ID: 38850572
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [ALL in adult patients: Contribution and limits of pediatric management].
    Rabian F; Boissel N
    Bull Cancer; 2021 Feb; 108(2):187-197. PubMed ID: 32981690
    [TBL] [Abstract][Full Text] [Related]  

  • 20. How should we treat older adults with Ph+ adult ALL and what novel approaches are being investigated?
    Wieduwilt MJ
    Best Pract Res Clin Haematol; 2017 Sep; 30(3):201-211. PubMed ID: 29050693
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.